Group Exercise in Cancer Patients Under Active Treatment: Feasibility Pilot Study.

NCT ID: NCT06825429

Last Updated: 2025-02-13

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

NA

Total Enrollment

50 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-03-31

Study Completion Date

2027-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of this study to investigate the feasibility in hospital reality, of a group exercise program for oncology patients under active treatment and evaluate its impact on some outcomes considered relevant from both clinical and subjective point of view.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The intervention will consist of EFG sessions lasting 45 minutes each, twice a week for 12 weeks to be carried out in the gym of the Rehabilitation Day Hospital.

Each 45-minute session includes an initial relaxation/stretching phase, simple aerobic exercises, muscle strengthening exercises, balance exercises, and will be led by a physiotherapist. The exercises proposed to the group with ECOG 2 will be less intense and of less difficulty with the aim of adapting the activity to patients with a lower performance status (see appendix 4.5, V2, 07/10/2024). The groups will consist of a minimum of five patients and a maximum of ten. Patients will also be stimulated to perform physical activity at home to a total of 150 minutes per week. Patients will be assessed at baseline (T0), at the end of the intervention (T1,12 weeks) and 6 months after the start of the intervention (T2).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Neoplastic Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Single-centre, uncontrolled interventional feasibility study
Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

ECOG 0-1

Each 45-minute session includes an initial relaxation/stretching phase, simple aerobic exercises, muscle strengthening exercises, balance exercises and will be led by a physiotherapist

Group Type EXPERIMENTAL

exercise programme for group with ECOG 0-1

Intervention Type PROCEDURE

exercise programme for group with ECOG 2

ECOG 2

The exercises proposed to the group with ECOG 2 will be less intense and less difficult with the aim of adapting the activity to patients with a lower performance status

Group Type EXPERIMENTAL

exercise programme for ECOG 2 group

Intervention Type PROCEDURE

this intervention shall be proportionated to the ECOG status of the group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

exercise programme for group with ECOG 0-1

exercise programme for group with ECOG 2

Intervention Type PROCEDURE

exercise programme for ECOG 2 group

this intervention shall be proportionated to the ECOG status of the group

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* neoplastic tumor
* age\>= 18
* prognosis\> 12 months
* ECOG \<=2
* Walking with/ without aids
* clinically stable
* signed informed consent
* Patients with bone metastases with ECOG from 0-1 suitable results

Exclusion Criteria

* sensory deficits who cannot perform physical exercise
* cognitive impairment that compromises collaboration and questionnaire filling
* patients with pathologies (e.g. neurological, psychiatric) that do not allow the obtaining of valid informed consent
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

IRCCS Azienda Ospedaliero-Universitaria di Bologna

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Besa Kopliku, MD

Role: PRINCIPAL_INVESTIGATOR

IRCCS Azienda Ospedaliero-Universitaria di Bologna

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Besa Kopliku, MD

Role: CONTACT

0512142285

Letizia Circosta, PT

Role: CONTACT

3383394823

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

EFG 21/22

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Effectiveness of a Cancer Exercise Program
NCT06039488 ENROLLING_BY_INVITATION NA
Activity and Cancer Survivorship Exercise Pilot
NCT07283029 ACTIVE_NOT_RECRUITING NA